Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas OlenckiRoberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, Rashmi Kumar

Research output: Contribution to journalReview article

60 Citations (Scopus)

Abstract

Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups - pure seminoma and nonseminoma - which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma.

Original languageEnglish (US)
Pages (from-to)772-799
Number of pages28
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number6
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Seminoma
Testicular Neoplasms
Guidelines
Germ Cell and Embryonal Neoplasms
Serum
Practice Guidelines
Testis
Neoplasms
Histology
Appointments and Schedules
Incidence
Testicular Germ Cell Tumor

ASJC Scopus subject areas

  • Oncology

Cite this

Motzer, R. J., Jonasch, E., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., ... Kumar, R. (2015). Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 13(6), 772-799.

Testicular cancer, version 2.2015 : Clinical pactice guidelines in oncology. / Motzer, Robert J.; Jonasch, Eric; Agarwal, Neeraj; Beard, Clair; Bhayani, Sam; Bolger, Graeme B.; Chang, Sam S.; Choueiri, Toni K.; Costello, Brian A.; Derweesh, Ithaar H.; Gupta, Shilpa; Hancock, Steven L.; Kim, Jenny J.; Kuzel, Timothy M.; Lam, Elaine T.; Lau, Clayton; Levine, Ellis G.; Lin, Daniel W.; Michaelson, M. Dror; Olencki, Thomas; Pili, Roberto; Plimack, Elizabeth R.; Rampersaud, Edward N.; Redman, Bruce G.; Ryan, Charles J.; Sheinfeld, Joel; Shuch, Brian; Sircar, Kanishka; Somer, Brad; Wilder, Richard B.; Dwyer, Mary; Kumar, Rashmi.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, No. 6, 01.06.2015, p. 772-799.

Research output: Contribution to journalReview article

Motzer, RJ, Jonasch, E, Agarwal, N, Beard, C, Bhayani, S, Bolger, GB, Chang, SS, Choueiri, TK, Costello, BA, Derweesh, IH, Gupta, S, Hancock, SL, Kim, JJ, Kuzel, TM, Lam, ET, Lau, C, Levine, EG, Lin, DW, Michaelson, MD, Olencki, T, Pili, R, Plimack, ER, Rampersaud, EN, Redman, BG, Ryan, CJ, Sheinfeld, J, Shuch, B, Sircar, K, Somer, B, Wilder, RB, Dwyer, M & Kumar, R 2015, 'Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 6, pp. 772-799.
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB et al. Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2015 Jun 1;13(6):772-799.
Motzer, Robert J. ; Jonasch, Eric ; Agarwal, Neeraj ; Beard, Clair ; Bhayani, Sam ; Bolger, Graeme B. ; Chang, Sam S. ; Choueiri, Toni K. ; Costello, Brian A. ; Derweesh, Ithaar H. ; Gupta, Shilpa ; Hancock, Steven L. ; Kim, Jenny J. ; Kuzel, Timothy M. ; Lam, Elaine T. ; Lau, Clayton ; Levine, Ellis G. ; Lin, Daniel W. ; Michaelson, M. Dror ; Olencki, Thomas ; Pili, Roberto ; Plimack, Elizabeth R. ; Rampersaud, Edward N. ; Redman, Bruce G. ; Ryan, Charles J. ; Sheinfeld, Joel ; Shuch, Brian ; Sircar, Kanishka ; Somer, Brad ; Wilder, Richard B. ; Dwyer, Mary ; Kumar, Rashmi. / Testicular cancer, version 2.2015 : Clinical pactice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2015 ; Vol. 13, No. 6. pp. 772-799.
@article{ea991fb84153432a80a447ed58f606d6,
title = "Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology",
abstract = "Germ cell tumors (GCTs) account for 95{\%} of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups - pure seminoma and nonseminoma - which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma.",
author = "Motzer, {Robert J.} and Eric Jonasch and Neeraj Agarwal and Clair Beard and Sam Bhayani and Bolger, {Graeme B.} and Chang, {Sam S.} and Choueiri, {Toni K.} and Costello, {Brian A.} and Derweesh, {Ithaar H.} and Shilpa Gupta and Hancock, {Steven L.} and Kim, {Jenny J.} and Kuzel, {Timothy M.} and Lam, {Elaine T.} and Clayton Lau and Levine, {Ellis G.} and Lin, {Daniel W.} and Michaelson, {M. Dror} and Thomas Olencki and Roberto Pili and Plimack, {Elizabeth R.} and Rampersaud, {Edward N.} and Redman, {Bruce G.} and Ryan, {Charles J.} and Joel Sheinfeld and Brian Shuch and Kanishka Sircar and Brad Somer and Wilder, {Richard B.} and Mary Dwyer and Rashmi Kumar",
year = "2015",
month = "6",
day = "1",
language = "English (US)",
volume = "13",
pages = "772--799",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "6",

}

TY - JOUR

T1 - Testicular cancer, version 2.2015

T2 - Clinical pactice guidelines in oncology

AU - Motzer, Robert J.

AU - Jonasch, Eric

AU - Agarwal, Neeraj

AU - Beard, Clair

AU - Bhayani, Sam

AU - Bolger, Graeme B.

AU - Chang, Sam S.

AU - Choueiri, Toni K.

AU - Costello, Brian A.

AU - Derweesh, Ithaar H.

AU - Gupta, Shilpa

AU - Hancock, Steven L.

AU - Kim, Jenny J.

AU - Kuzel, Timothy M.

AU - Lam, Elaine T.

AU - Lau, Clayton

AU - Levine, Ellis G.

AU - Lin, Daniel W.

AU - Michaelson, M. Dror

AU - Olencki, Thomas

AU - Pili, Roberto

AU - Plimack, Elizabeth R.

AU - Rampersaud, Edward N.

AU - Redman, Bruce G.

AU - Ryan, Charles J.

AU - Sheinfeld, Joel

AU - Shuch, Brian

AU - Sircar, Kanishka

AU - Somer, Brad

AU - Wilder, Richard B.

AU - Dwyer, Mary

AU - Kumar, Rashmi

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups - pure seminoma and nonseminoma - which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma.

AB - Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups - pure seminoma and nonseminoma - which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma.

UR - http://www.scopus.com/inward/record.url?scp=84932172812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932172812&partnerID=8YFLogxK

M3 - Review article

C2 - 26085393

AN - SCOPUS:84932172812

VL - 13

SP - 772

EP - 799

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 6

ER -